The FDA has received 22,745 adverse event reports for dogs that name Melarsomine.
- 22,745 reports name Melarsomine in dogs, which is 2.3% of all 1,001,380 dog reports. A report counts under every active ingredient it names.
- 41% are marked serious and 5.8% record a death or euthanasia; across all dog reports those figures are 29% and 5.4%.
- 33% are complaints that the product did not work (38% across all dog reports).
- The clinical signs reported most are ineffective, heartworm adults, lack of efficacy (endoparasite) - heartworm and vomiting.
- The FDA lists 2 approved animal drug applications containing Melarsomine for dogs, the earliest approved in 2017.
- None of this is a rate. The FDA data does not record how many dogs were given Melarsomine, so it cannot say how often any of this happens.
How the reports break down
| What the reports say | Reports | Share of this medicine's reports | All dog reports |
|---|---|---|---|
| Marked seriousthe FDA record flags the report as serious | 9,278 | 41% | 29% |
| Death or euthanasiathe outcome recorded in the report, with no finding of cause | 1,311 | 5.8% | 5.4% |
| Did not worka complaint that the product failed to work, which the FDA files as an adverse event | 7,405 | 33% | 38% |
| Seizurea seizure or convulsion is among the clinical signs | 446 | 2.0% | 4.4% |
| Not used per labelthe report says the product was not used the way its label directs | 4,505 | 20% | 21% |
Where on the body do the reported signs sit?
Not on the body: Did not work 28% Whole body 14%
- Did not work28%ineffective, heartworm adults, lack of efficacy (endoparasite) - heartworm, ineffective, heartworm larvae, lack of efficacy
- Stomach and gut23%vomiting, anorexia, diarrhoea, hypersalivation and 2 more
- Where it was applied15%injection site swelling, injection site pain, injection site lump
- Whole body14%pain, lethargy, fever, death
- Heart and breathing9.7%cough, panting, polypnoea, cardiac disorder
- Behaviour5.2%depression, restlessness
- Blood and organ tests3.0%elevated alanine aminotransferase (alt)
- Brain and nerves1.8%ataxia
Each figure is a share of sign mentions among the 25 signs reported most for Melarsomine in dogs. One report can list several signs, so these do not add up to reports. The grouping into body systems is ours; the signs in each group are listed beside it.
Clinical signs reported most
- INEFFECTIVE, HEARTWORM ADULTS4,219 19%
- Lack of efficacy (endoparasite) - heartworm2,840 12%
- Vomiting2,736 12%
- Injection site swelling2,292 10%
- Injection site pain1,470 6.5%
- Pain1,286 5.7%
- Anorexia1,220 5.4%
- Diarrhoea1,192 5.2%
Reports received per year
Is it approved for dogs?
The FDA lists 2 approved animal drug applications containing Melarsomine for dogs, the earliest approved in 2017.
| Product | Form | Approved for | First approved | FDA application |
|---|---|---|---|---|
| DirobanAnzac Animal Health, LLC | Powder RX | Dog | 2017 | 200-609 |
| Immiticide Sterile PowderBoehringer lngelheim Animal Health USA, Inc. | Liquid (Solution) RX | Dog | 141-042 |
From the FDA record for Diroban: <p>Not for use in breeding animals and lactating or pregnant bitches. The drug is contraindicated in dogs with class 4 (very severe) heartworm disease (Caval Syndrome). Administer only by deep intramuscular injection in the lumbar muscles (L3 - L5). [continues in the FDA record]
What can you do next?
Report counts: FDA Center for Veterinary Medicine adverse event reports, read 11 November 2026 (FDA data last updated 5 October 2026). Approvals: Animal Drugs @ FDA, read 11 November 2026. Counts are reports, not animals and not doses.
Where can you go from this result?
This result is one of 94 in the lookup. Open it in the lookup to set it beside another medicine, or read how the counts were collected.
- Bedinvetmab in dogs19,619
- Imidacloprid in dogs17,831
- Oclacitinib in dogs28,973
- Selamectin in dogs29,523
To report a suspected side effect in your own animal, follow how to report an animal drug side effect to the FDA. The FDA explains what a report can and cannot show in openFDA's guide to reading the results.
Compiled by Vincent Wesley Couey, PetMaxxing Research (ORCID 0009-0005-6869-308X). Sources: openFDA animal and veterinary adverse event interface; Animal Drugs @ FDA.